Although numerous genetic studies have been conducted for bipolar disorder (BD), its genetic architecture remains elusive. Here we perform, to the best of our knowledge, the first trio-based exome sequencing study for BD to investigate potential roles of de novo mutations in the disease etiology. We identified 71 de novo point mutations and one de novo copy-number mutation in 79 BD probands. Among the genes hit by de novo loss-of-function (LOF; nonsense, splice site or frameshift) or protein-altering (LOF, missense and inframe indel) mutations, we found significant enrichment of genes highly intolerant (first percentile of intolerant genes assessed by Residual Variation Intolerance Score) to protein-altering variants in general population, an observation that is also reported in autism and schizophrenia. When we performed a joint analysis using the data of schizoaffective disorder in published studies, we found global enrichment of de novo LOF and protein-altering mutations in the combined group of bipolar I and schizoaffective disorders. Considering relationship between de novo mutations and clinical phenotypes, we observed significantly earlier disease onset among the BD probands with de novo protein-altering mutations when compared with non-carriers. Gene ontology enrichment analysis of genes hit by de novo protein-altering mutations in bipolar I and schizoaffective disorders did not identify any significant enrichment. These results of exploratory analyses collectively point to the roles of de novo LOF and protein-altering mutations in the etiology of bipolar disorder and warrant further large-scale studies.
INTRODUCTION
Bipolar disorder (BD) is a severe mental disorder characterized by recurrent manic and depressive episodes with a lifetime prevalence~1%. 1, 2 Epidemiological studies have consistently indicated significant contribution of genetic factors to the etiology of BD, and its heritability (broad-sense heritability that considers both the additive and non-additive genetic factors) calculated from the concordance rates in monozygotic and dizygotic twins is 85%. 3 Because of this high heritability a number of genetic studies for BD have been conducted. However, linkage studies using family samples could not robustly identify causative genes. 4 More recently genome-wide association studies (GWAS) have identified single-nucleotide polymorphisms certainly associated with BD in several genes such as CACNA1C encoding a plasma membrane L-type Ca 2+ channel, 5, 6 whereas the effect size of each robustly associated single-nucleotide polymorphism is tiny (typically only increases the risk by 1.1-1.2 fold) and a large part of the disease heritability cannot be explained even if hundreds of thousands of weakly associated common single-nucleotide polymorphisms are considered. 7 This phenomenon is termed as the 'missing heritability', and potential roles of rare variants that have not been investigated in GWAS are drawing increasing attention.
As one of the proofs for the hypothesis that rare variants could have a significant role in the genetic architecture of BD, recent whole-genome sequencing of 200 individuals from 41 bipolar families showed the role of rare transmitted variants in neuronal excitability related genes including those encoding calcium channels. 8 In addition to rare transmitted variants, de novo (newly arising) mutations could be another class of genetic variation that explains a part of the missing heritability (note that de novo mutations explain a part of 'broad-sense' heritability while these are not inherited 9 ). Indeed, recent studies have implicated contribution of de novo copy-number variations (CNVs) to the risk for BD, 10, 11 particularly patients with an early onset. 10 In addition to CNVs, de novo point mutations, whose frequency increases as paternal age advances, 12 could have an important role in BD, because it has been well known that an older age of the father increases risk for BD in the offspring. 13, 14 However, to our knowledge there has been no study reporting results of comprehensive analysis of de novo point mutations in BD, whereas their significant contribution to the genetic architectures of various neuropsychiatric disorders including autism spectrum disorder (ASD) [15] [16] [17] [18] [19] [20] [21] and schizophrenia [22] [23] [24] [25] [26] [27] [28] has been consistently reported in recent whole-exome sequencing (WES) studies that analyze all coding exons in the human genome.
To address the question whether de novo point mutations contribute to the genetic architecture of BD, here we performed, to the best of our knowledge, the first trio-based WES study for BD by analyzing 237 exomes.
MATERIALS AND METHODS

Studied subjects
We used DNA samples from 79 trios with a BD proband (56 with bipolar I disorder (BDI) and 23 with bipolar II disorder (BDII)) and unaffected parents. All the probands were diagnosed with BDI or BDII based on the DSM (Diagnostic and Statistical Manual of Mental Disorders) IV criteria by trained psychiatrists. All the parents were screened for mental disorders by structured interview using M.I.N.I. (Mini International Neuropsychiatric Interview). 29 See Supplementary Information for more detailed information. The study was approved by the First Committee of Research Ethics of RIKEN Wako Institute and the Institutional Review Board of Yamaguchi University Hospital.
Exome sequencing, data processing, variant calling and identification of de novo mutations Genomic DNA from either peripheral blood or saliva was subjected to target capturing using the SureSelect XT Human All Exon kits V4, V5 or V5 + mitochondria (Agilent Technologies, Santa Clara, CA; detailed information is available in Supplementary  Table 1) . WES was performed by using either the HiSeq2000 or HiSeq2500 (Illumina, San Diego, CA, USA) with paired-end 101 bp reads. Generated sequence data (fastq files) were processed by using the pipeline with BWA-MEM 30 (version 0.7.5a), SAMtools,
31
Picard (version 1.92, http://picard.sourceforge.net/) and GATK
32
(version 2.6-4). Variant calls were made by using the GATK best practices recommendations. 33 Identified candidates for de novo mutations were subjected to validation experiments by amplification using PCR followed by standard Sanger sequencing. De novo CNVs were identified by using exome hidden Markov model (XHMM) [34] [35] [36] and copy-number inference from exome reads (CoNIFER) 37 and validated by comparative genome hybridization arrays. See Supplementary Information for more detailed information.
Analyses of genes hit by de novo mutations using RVIS We assigned Residual Variation Intolerance Score (RVIS) representing 'gene intolerance' to protein-altering genetic variation in general population to each gene hit by a de novo mutation using Dataset 2 of Petrovski et al. 38 Among the 70 genes with de novo mutations in our BD cohort, 66 genes were assigned for RVIS and used for the subsequent analyses. In Petrovski et al., 38 the hypothesized probability that a de novo mutation hit the first quartile of the most intolerant genes was calculated as 38% considering gene sizes. This was because, Total coding length of the first quartile of intolerant genes Total coding length of all genes ¼ 0:38:
We obtained the data of coding length for each gene assigned for RVIS using UCSC Therefore if a mutation is randomly generated, the probabilities to hit the first percentile and the first quartile of the intolerant genes are 4% and 38%, respectively. On the basis of these hypothesized probabilities (4% for the first percentile and 38% for the first quartile), we evaluated whether the first percentile and the quartile of 'intolerant genes' are enriched among the genes hit by three types of mutations (that is, loss-of-function (LOF), proteinaltering and synonymous) in our cohort using one-tailed binominal exact test. For example, there are 53 genes with a de novo protein-altering mutation in BD for which RVIS is available. If 53 mutations are randomly generated, the expected number of first percentile of intolerant genes hit by a protein-altering mutations is 53 × 0.04 = 2.1, whereas we observed that six genes were among the first percentile of the intolerant genes in the real data set for BD. On the basis of these observations, we performed one-tailed binominal exact test with the following numbers; the number of success (x) = 6, the number of trials (n) = 53 and the hypothesized probability of success (p) = 0.04. The corresponding commend for R software we used for the analysis was binom.test (x = 6, n = 53, p = 0.04, alternative = "greater").
Enrichment analysis of LOF and protein-altering de novo mutations in case subjects Global enrichment of de novo LOF and protein-altering mutations in case subjects were examined by one-tailed Fisher's exact test using the reported data of 1911 unaffected siblings. 39 For an extended analysis, published data on schizoaffective disorder (SAD) 24, 27 was combined with the current data set of BD. Details are described in Supplementary Information.
Procedures for gene ontology (GO) enrichment analysis of de novo LOF and protein-altering mutations and other analyses are detailed in Supplementary Information.
RESULTS
Identification of de novo point mutations in bipolar disorder
We performed WES of 237 DNA samples from a cohort consisting of 79 probands affected with BD and their parents without major psychoses (that is, BD, schizophrenia and SAD, Supplementary Table 1 ). On average 92.5% of the targeted exome regions were covered by 20 or more reads at the individual level. At the trio level, on average 88.9% of the targets were covered by 20 or more reads in all three members (Supplementary Figure 1) . Among the 79 trios, we identified 71 de novo point mutations (singlenucleotide variations (SNVs) and short insertion/deletions (indels)) in 70 genes, which were validated by Sanger sequencing (Table 1  and Supplementary Table 2 ). As two missense mutations in DOCK10 were identified in the same individual on the same sequencing reads with an interval of four bases, we considered these mutations as a single missense mutation event (thus there are 70 de novo events). These 70 de novo events comprise of 64 SNVs (including the composite mutation noted above) and six indels, including four nonsense mutations, one canonical splice site mutation, 45 missense mutations, 14 synonymous mutations, four frameshift indels (of which two mutations directly introduce a stop codon) and two inframe indels. The number of de novo mutations in each proband ranged from zero to four. Forty-two probands carried one or more de novo mutations. Per-individual number of de novo mutations was 0.89, which is similar to those reported in the largest family-based WES studies for ASD 20 (0.94 for ASD and 0.84 for unaffected siblings, based on re-annotated data using our analytical pipelines) and schizophrenia 26 (0.90 for schizophrenia) to date.
Identification of de novo CNV from exome sequencing data We next analyzed CNVs using our WES data. For this purpose we used two software, XHMM [34] [35] [36] and CoNIFER, 37 both of which were specifically developed to detect CNVs from WES data sets. We identified a de novo deletion of approximately 0.2 Mbp at 3q29 including ATP13A3, TMEM44, LSG1 and FAM43A (approximated position in hg19 = chr3: 194.2 -194.4M), which was confirmed by comparative genome hybridization arrays (Supplementary Figure 2) . This de novo deletion is located at~1.3 Mbp upstream of the known 3q29 deletion syndrome locus, whose nominal association with BD was recently reported. 40 In addition to direct disruption of the genes included in the CNV region, this deletion may have some regulatory impact on genes in the 3q29 deletion syndrome locus. developed RVIS, a scoring system to assess intolerance of individual genes to protein-altering variants based on large-scale WES data of general population. By using RVIS it has been demonstrated that genes hit by de novo LOF (nonsense, splice site and frameshift; all of these are expected to totally disrupt the protein sequence) and protein-altering (that is, LOF, missense and inframe indel) mutations in ASD and schizophrenia are enriched for the first quartile (25 percentile) of intolerant genes, 28, 38 and rare transmitted LOF variants in the first percentile of highly intolerant genes are enriched in ASD probands when compared with their healthy siblings. 41 Among 70 genes hit by de novo mutations in BD, 66 genes were assigned for RVIS. When we analyzed gene intolerance by classifying mutations according to their predicted functionality (that is, LOF, protein-altering or synonymous), we found that genes with de novo LOF mutations or protein-altering mutations are significantly enriched for the first percentile of intolerant genes (Figures 1a, P = 4.5 × 10 − 3 for LOF and P = 0.019 for any protein-altering mutations, one-tailed binominal exact test, see Materials and Methods for details), whereas there was no enrichment in genes with synonymous mutations (P = 1). A similar trend was observed when we analyzed for the first quartile of intolerant genes (P = 0.079 for LOF, P = 0.067 for protein-altering and P = 0.79 for synonymous mutations). These findings equivalent to those for ASD and schizophrenia, for which roles of de novo mutations are established, suggest contribution of de novo mutations, particularly de novo LOF and protein-altering mutations in intolerant genes, to the genetic etiology of BD.
According to these results and previous WES studies for ASD and schizophrenia mostly reporting global enrichment of de novo LOF and protein-altering mutations in case subjects, [20] [21] [22] 24, 25, 27, 28, 42 we also tested whether there is global excess of these mutations in BD. For this purpose, we compared the numbers of de novo LOF or protein-altering mutations and de novo synonymous mutations between our BD probands and a large cohort of control subjects (1911 unaffected siblings in Iossifov et al. 20 ), because this method using synonymous mutations as an internal control should be resistant to potential artifacts caused by comparison of data from different studies. There was no statistically significant enrichment of de novo LOF and protein-altering mutations in BD (odds ratio (OR) = 1.48, P = 0.244, for LOF mutations, OR = 1.30, P = 0.233 for proteinaltering mutations, one-tailed Fisher's exact test, Figure 1b) .
Considering relationship between de novo mutations and clinical phenotypes in our BD cohort, we observed that there is significant difference in age of onset between the probands carrying one or more de novo protein-altering mutations and the probands with no protein-altering mutation (Figure 1c , two-tailed Student's t-test, P = 0.013, average age of onset ± s.d. = 21.6 ± 6.1 in mutation carriers and 25.9 ± 8.8 in non-carriers), while there was no significant difference in age of ascertainment between these two groups.
Global enrichment of de novo LOF and protein-altering mutations in BDI and SAD As a moderate sample size in our cohort limit the statistical power, we next performed a joint analysis by combining our data set and the published data for patients with SAD 43 characterized by both the mood and psychotic symptoms and shares genetic background with BD 44 (no. of trios = 143; 79 BD from our cohort, 63 SAD from Xu et al., 24 and one SAD from MaCarthy et al. 27 ). In the analysis comparing this combined group of BD and SAD to controls (1911 unaffected siblings in Iossifov et al. 20 as described above), we observed a trend toward enrichment of de novo LOF and protein-altering mutations (P = 0.085, OR = 1.73 for LOF mutations, P = 0.073, OR = 1.47 for protein-altering mutations, Figure 1b ). In addition, when we focused on the severer group, patients with BDI or SAD, there was statistically significant enrichment of de novo LOF and protein-altering mutations in the case group (P = 0.030, OR = 2.30 for LOF mutations, P = 0.021, OR = 1.87 for protein-altering mutations, Figure 1b) , whereas further large-scale studies should be required to conclude enrichment of these mutations.
GO enrichment analysis of the genes hit by de novo proteinaltering mutations On the basis of the results of our analyses showing global enrichment of de novo protein-altering mutations in BDI and SAD, we next exploratory investigated whether there are specific GO terms overrepresented among the genes hit by these mutations in the combined group of BDI and SAD. We first performed a GO enrichment analysis with the Database for Annotation, Visualization and Integrated Discovery (DAVID, v6 .7) 45,46 using the list of genes hit by de novo protein-altering mutations in BDI and SAD as an input (no. of genes = 75, Supplementary Table 3 ). There was no GO term with significant enrichment after performing correction for multiple testing. Non-significant trend of enrichment was found for nine GO terms including 'calcium ion binding (GO:0005509)', 'serine-type peptidase activity (GO:0008236)' and 'tissue morphogenesis (GO:0048729)' (Figure 2a) . To test whether the suggestive enrichment of these terms are noteworthy, we performed a simulation analysis by randomly selecting 75 de novo proteinaltering mutations, equal to the number of mutations in BDI and SAD, from the list of de novo protein-altering mutations reported in control subjects 20 10 000 times (Figure 2b , see Supplementary Information for details). We counted how many times nominally significant enrichment of a given GO term was observed, and the probability to see significant enrichment among 10 000 trials was considered as the P-value. If the enrichment observed in our DAVID analysis is explained by artifacts due to use of genes harboring de novo mutations as an input (for example, the input genes should be biased toward large genes because such genes have higher chance to be hit by de novo mutations), significant enrichment should not be observed in this simulation analysis. Three GO terms showed non-significant results in the simulation analysis. We observed nominally significant enrichment (uncorrected P-value o 0.05 in the simulation analysis) of six GO terms; 'calcium ion binding (GO:0005509)', 'tissue morphogenesis (GO:0048729)', 'serine-type peptidase activity (GO:0008236)', 'serine hydrolase activity (GO:0017171)', 'embryonic morphogenesis (GO:0048598)' and 'protein homodimerization activity (GO:0042803)'. However, this enrichment was no more significant after the correction for multiple testing with the number of terms subjected to the simulation analysis, except for 'serine-type peptidase activity (GO:0008236)' and 'serine hydrolase activity (GO:0017171)'. Individual genes with a de novo protein-altering mutation included in each term are detailed in Figure 2a .
New candidate genes for bipolar disorder The list of genes harboring de novo mutations in BD could help identification of promising new candidate genes for BD.
According to the 'ascertainment differentials', the differences in the frequencies of each class of mutation in two populations 20, 47 calculated from per-individual rates of de novo LOF or proteinaltering mutations in our BD cohort and control subjects (1911 unaffected siblings in Iossifov et al., 20 see Supplementary Information for details), roughly 22% and 9% of de novo LOF and protein-altering mutations in BD could contribute to the diagnosis of BD, respectively. This indicates that genes with de novo LOF mutations should be particularly enriched for genuine disease susceptibility genes. Among nine genes with a de novo LOF mutation, we found enrichment of genes highly intolerant to functional variation as described above. These genes hit by a LOF mutation despite their high intolerance, EHD1, KLF4, KMT2C, MACF1, UNC13B and XPO4 (Table 2) , should be good candidates for disease susceptibility genes. Previous studies have pointed out genes hit by multiple de novo protein-altering mutations, particularly LOF mutations, are highly likely to be genuine disease genes. [48] [49] [50] Although there was no gene with two or more de novo protein-altering mutations in our BD cohort or the combined group of BD and SAD, when we compared the list of genes hit by de novo protein-altering mutations in BD with the list for schizophrenia (excluding known cases of SAD) we found six genes hit by de novo protein-altering mutations in BD and also in schizophrenia (BZRAP1, DNAH9, GLI3, KMT2C, LCT and MACF1, Table 2 ). Although the P-values for observed numbers of de novo protein-altering mutations in these genes (calculated by the procedures described in Samocha et al., 49 see Supplementary Information for details) do not reach to the exome-wide significance threshold (P = 2.5 × 10 − 6 , considering the number of coding genes, Table 2 ), some of them could be good candidates for genes associated with BD and schizophrenia that share genetic risk factors. 51, 52 
DISCUSSION
In this study reporting results of the first trio-based WES for BD, we identified 71 de novo point mutations and one de novo CNV in 79 probands. By exploring the properties of de novo mutations and genes hit by these mutations in BD, we observed significant enrichment of de novo LOF mutations hitting genes highly intolerant to functional variants as well as a trend toward global excess of de novo LOF and protein-altering mutations. In the joint analysis combining our data of BD and the data of SAD in published studies, we observed global enrichment of LOF and proteinaltering mutations in the severer group of patients consisting of BDI and SAD, implicating contribution of these mutations to the genetic etiology. Our analysis of relationship between clinical phenotypes and de novo protein-altering mutations revealed significantly earlier age at onset in probands with one or more such mutations than non-carriers. This observation is in line with a previous study reporting stronger association of de novo CNVs with early-onset BD. 10 Although further large-scale studies are required to prove the pathogenic role of de novo mutations in BD, given the moderate sample size and statistical significance in this study, our observations would be credible considering the fact that similar results have been reported for ASD and schizophrenia. De novo SNVs reportedly increase with advanced paternal age. 45, 46 (uncorrected raw P-values). P_Simulation indicates P-values calculated by a simulation analysis using the data of de novo protein-altering mutations in control subjects (1911 unaffected siblings in Iossifov et al. 20 ). For P_Simulation, both the raw P-values and Pvalues corrected for the number of terms subjected to the simulation analysis (# = 9, Bonferroni procedure) were noted. Boldface indicates genes with a de novo loss-of-function (LOF) mutation in bipolar disorder (BD). Genes with de novo mutations identified in SAD 24, 27 are shown in parentheses. (b) Histograms represent the distribution of hit counts in the simulation analyses (10 000 iterations) for seven GO terms. Dotted lines indicate the observed hit counts (obs.) and the corresponding P-values.
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In a disease with constant prevalence rate despite reduced reproduction fitness, genetic risk factors are assumed to be constantly supplied as de novo mutations. Because the risk for BD is associated with advanced paternal age 13, 14 and BD patients show reduced reproduction fitness, 53, 54 albeit less so than in schizophrenia and ASD, 53 it is plausible that de novo SNVs have a role in etiology of BD.
In our GO enrichment analyses of genes hit by de novo proteinaltering mutations in BDI and SAD, we identified nominal enrichment of six GO terms. Among them, enrichment of 'serinetype peptidase activity (GO:0008236)' and 'serine hydrolase activity (GO:0017171)' remained significant when we considered the number of terms subjected to our simulation analysis, suggesting potential involvement of this pathway in the pathophysiology of BD. In addition, identification of 'calcium ion binding (GO:0005509)' as one of nominally enriched terms should be of interest, because this result is in line with findings in previous genetic, biochemical and pharmacological studies for BD. For instance, association of several voltage-dependent calcium channel genes such as CACNA1C and CACNA1B was reported in large-scale GWAS for BD. 5, 55 A pathway analysis of GWAS data suggests enrichment of calcium channel-related pathways among the genes empirically associated with BD. 56 Studies of peripheral blood cells have consistently demonstrated altered intracellular calcium signaling in BD. 57, 58 Lithium, the first-line therapeutic drug for BD, modulates inositol-mediated pathways 59 and thereby regulate calcium ion release from the endoplasmic reticulum. 60 When we performed a GO enrichment analysis using DAVID 45, 46 by integrating the data of de novo protein-altering mutations in our study, common singlenucleotide polymorphisms associated with BD in a large-scale GWAS 5 and rare CNVs implicated in BD 40 (total no. of unique input genes = 229, see Supplementary Information for details), 'calcium signaling pathway (hsa04020)' was the only term significantly enriched after performing correction for multiple testing (P corrected = 6.4 × 10 − 3 , Bonferroni correction; note that significant enrichment of 'calcium signaling pathway (hsa04020)' after correction was not observed when we submitted candidate genes from each study). This result of an integrative analysis indicates that various types of genetic evidence for BD could converge on the calcium signaling pathway.
When we looked at individual genes carrying a de novo mutation to search for promising candidate genes, we found that KMT2C, MACF1 and UNC13B are hit by a de novo LOF mutation despite their extremely high intolerance to protein-altering variants 38 ( Table 1) . KMT2C (also known as MLL3) encodes a catalytic subunit of histone methyltransferase protein complex specifically mediating mono-, di-and tri-methylation of histone H3 at lysine 4 (H3K4). Identification of a de novo LOF mutation in this gene that is also hit by de novo protein-altering mutations in ASD and schizophrenia 17, 21, 26 could be in line with accumulating evidence pointing out important roles of chromatin regulator genes in neuropsychiatric disorders. 21, 27, 28, 61, 62 MACF1 (also known as ACF7) encodes the microtubule actin cross-linking factor 1 protein that has an essential role in integration of microtubule dynamics. 63 This gene categorized as a 'calcium ion binding (GO:0005509)' gene is involved in calcium-induced reorganization of the cytoskeleton. 64 Interestingly, binding of MACF1 to microtubules is regulated by GSK3β, 65 a key enzyme implicated in the mechanism of action of lithium.
66 UNC13B (also known as MUNC13) encodes a presynaptic protein with an essential role in synaptic vesicle priming. Although this gene is not classified as a 'calcium ion binding (GO:0005509)' gene, UNC13B forms a complex with calmodulin, a calcium ion binding protein, and this complex regulates synaptic vesicle priming and synaptic efficacy in response to residual calcium ion signals, 67 further suggesting involvement of the calcium signaling pathway in the BD pathophysiology. Besides these three genes, EHD1 could be another promising candidate gene in the context of possible relationship between BD and the calcium signaling pathway. This gene carrying a de novo LOF mutation in BD encodes a calcium binding protein involved in regulation of synaptic endocytosis and exocytosis. 68, 69 In addition, our preliminary experiments indicate that the de novo frameshift mutation in EHD1 at the last exon of this gene cause expression of the protein lacking EF-hand calcium binding domain by escaping nonsense-mediated mRNA decay (Supplementary Figure 3) . This truncated form of EHD1 protein may have a dominant negative effect. These four genes could be Number of expected mutations were calculated by using per-gene mutation rates provided in Samocha et al.
b
P-values calculated by invoking Poisson distribution probabilities. Lower RVIS and RVIS percentile indicate that the gene is less tolerant to protein-altering variants.
particularly good candidates for disease susceptibility genes for BD, and it would be worthwhile to subject these genes to target resequencing. 70 In summary, we performed the first trio-based WES study for BD and demonstrated potential roles of de novo protein-altering mutations and calcium-related genes in the disease etiology. These findings are in accordance with the results of previous WES studies for other neuropsychiatric disorders with reduced fecundity such as ASD and schizophrenia, and with the evidence from various types of studies for BD. Our results could provide important insights into the genetic architecture and biology of BD, and warrant further large-scale studies in order to understand the roles of de novo and rare mutations in BD more precisely, and to identify robust disease-associated genes/mutations with a large effect size.
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